Dr. Dietrich is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1048 Harvin Way
Rockledge, FL 32955Phone+1 321-636-2111Fax+1 321-636-7180
Education & Training
University of Texas Southwestern Medical CenterFellowship, Hematology and Medical Oncology, 2012 - 2015- University of Texas Southwestern Medical CenterResidency, Internal Medicine, 2010 - 2012
Ruprecht Karl University Faculty of MedicineClass of 2006
Certifications & Licensure
FL State Medical License 2016 - 2026
TX State Medical License 2012 - 2017- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- 837 citationsMechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemiaMarina Konopleva, Rooha Contractor, Twee Tsao, Ismael Samudio, Peter P. Ruvolo
Cancer Cell. 2006-11-01 - 505 citationsDirect evidence of mesenchymal stem cell tropism for tumor and wounding microenvironments using in vivo bioluminescent imaging.Shannon Kidd, Erika L. Spaeth, Jennifer L. Dembinski, Martin Dietrich, Keri Watson
Stem Cells. 2009-10-01 - 142 citationsMesenchymal stromal cells alone or expressing interferon-β suppress pancreatic tumors in vivo, an effect countered by anti-inflammatory treatmentShannon Kidd, Lisa Caldwell, Martin Dietrich, Ismael Samudio, Erika L. Spaeth
Cytotherapy. 2010-09-01
Press Mentions
FDA Expands Indication for Amivantamab in Lung CancerSeptember 23rd, 2024- JnJ Gets USFDA Nod for Rybrevant plus Standard of Care Chemotherapy for Lung Cancer TreatmentSeptember 21st, 2024
- RYBREVANT® (Amivantamab-Vmjw) plus Standard of Care Approved in the U.S. As First and Only Targeted Regimen to Cut Risk of Disease Progression by More Than Half in Second-Line EGFR-Mutated Advanced Lung CancerSeptember 19th, 2024
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
